Corticosteroids in acute respiratory distress syndrome

Improving the course and outcome of patients with acute respiratory distress syndrome presents a challenge. By understanding the immune status of a patient, physicians can consider manipulating proinflammatory systems more rationally. In this context, corticosteroids could be a therapeutic tool in t...

Full description

Bibliographic Details
Main Authors: A.B.S. Fernandes, W.A. Zin, P.R.M. Rocco
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2005-02-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000200003
id doaj-5036b3b53c9249d29bfc0742adf1c32d
record_format Article
spelling doaj-5036b3b53c9249d29bfc0742adf1c32d2020-11-24T20:57:56ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2005-02-0138214715910.1590/S0100-879X2005000200003Corticosteroids in acute respiratory distress syndromeA.B.S. FernandesW.A. ZinP.R.M. RoccoImproving the course and outcome of patients with acute respiratory distress syndrome presents a challenge. By understanding the immune status of a patient, physicians can consider manipulating proinflammatory systems more rationally. In this context, corticosteroids could be a therapeutic tool in the armamentarium against acute respiratory distress syndrome. Corticosteroid therapy has been studied in three situations: prevention in high-risk patients, early treatment with high-dose, short-course therapy, and prolonged therapy in unresolving cases. There are differences between the corticosteroid trials of the past and recent trials: today, treatment starts 2-10 days after disease onset in patients that failed to improve; in the past, the corticosteroid doses employed were 5-140 times higher than those used now. Additionally, in the past treatment consisted of administering one to four doses every 6 h (methylprednisolone, 30 mg/kg) versus prolonging treatment as long as necessary in the new trials (2 mg kg-1 day-1 every 6 h). The variable response to corticosteroid treatment could be attributed to the heterogeneous biochemical and molecular mechanisms activated in response to different initial insults. Numerous factors need to be taken into account when corticosteroids are used to treat acute respiratory distress syndrome: the specificity of inhibition, the duration and degree of inhibition, and the timing of inhibition. The major continuing problem is when to administer corticosteroids and how to monitor their use. The inflammatory mechanisms are continuous and cyclic, sometimes causing deterioration or improvement of lung function. This article reviews the mechanisms of action of corticosteroids and the results of experimental and clinical studies regarding the use of corticosteroids in acute respiratory distress syndrome.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000200003Acute respiratory distress syndromeCollagenCytokineMethylprednisoloneExperimental modelsClinical trials
collection DOAJ
language English
format Article
sources DOAJ
author A.B.S. Fernandes
W.A. Zin
P.R.M. Rocco
spellingShingle A.B.S. Fernandes
W.A. Zin
P.R.M. Rocco
Corticosteroids in acute respiratory distress syndrome
Brazilian Journal of Medical and Biological Research
Acute respiratory distress syndrome
Collagen
Cytokine
Methylprednisolone
Experimental models
Clinical trials
author_facet A.B.S. Fernandes
W.A. Zin
P.R.M. Rocco
author_sort A.B.S. Fernandes
title Corticosteroids in acute respiratory distress syndrome
title_short Corticosteroids in acute respiratory distress syndrome
title_full Corticosteroids in acute respiratory distress syndrome
title_fullStr Corticosteroids in acute respiratory distress syndrome
title_full_unstemmed Corticosteroids in acute respiratory distress syndrome
title_sort corticosteroids in acute respiratory distress syndrome
publisher Associação Brasileira de Divulgação Científica
series Brazilian Journal of Medical and Biological Research
issn 0100-879X
1414-431X
publishDate 2005-02-01
description Improving the course and outcome of patients with acute respiratory distress syndrome presents a challenge. By understanding the immune status of a patient, physicians can consider manipulating proinflammatory systems more rationally. In this context, corticosteroids could be a therapeutic tool in the armamentarium against acute respiratory distress syndrome. Corticosteroid therapy has been studied in three situations: prevention in high-risk patients, early treatment with high-dose, short-course therapy, and prolonged therapy in unresolving cases. There are differences between the corticosteroid trials of the past and recent trials: today, treatment starts 2-10 days after disease onset in patients that failed to improve; in the past, the corticosteroid doses employed were 5-140 times higher than those used now. Additionally, in the past treatment consisted of administering one to four doses every 6 h (methylprednisolone, 30 mg/kg) versus prolonging treatment as long as necessary in the new trials (2 mg kg-1 day-1 every 6 h). The variable response to corticosteroid treatment could be attributed to the heterogeneous biochemical and molecular mechanisms activated in response to different initial insults. Numerous factors need to be taken into account when corticosteroids are used to treat acute respiratory distress syndrome: the specificity of inhibition, the duration and degree of inhibition, and the timing of inhibition. The major continuing problem is when to administer corticosteroids and how to monitor their use. The inflammatory mechanisms are continuous and cyclic, sometimes causing deterioration or improvement of lung function. This article reviews the mechanisms of action of corticosteroids and the results of experimental and clinical studies regarding the use of corticosteroids in acute respiratory distress syndrome.
topic Acute respiratory distress syndrome
Collagen
Cytokine
Methylprednisolone
Experimental models
Clinical trials
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000200003
work_keys_str_mv AT absfernandes corticosteroidsinacuterespiratorydistresssyndrome
AT wazin corticosteroidsinacuterespiratorydistresssyndrome
AT prmrocco corticosteroidsinacuterespiratorydistresssyndrome
_version_ 1716787173445861376